Natco Pharma launches Nexavar Tablets in partnership with Viatris; stock climbs ~3%

1 Jun 2022 , 11:03 AM

Natco Pharma Limited announced the launch of the first generic version of Nexavar (Sorafenib) Tablets in 200 mg strength today in the U.S. market.

NATCO’s commercial partner Viatris, a global pharmaceutical company will launch the product.

As per company’s filing with the exchanges, Sorafenib is prescribed for the treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC), and Differentiated Thyroid Carcinoma (DTC). 

As per industry sales data, Nexavar registered sales of USD 69.7 million for the year ending December 2021.

Natco Pharma is currently trading at Rs713.75 up by Rs21.7 or 3.14% from its previous closing of Rs692.05 on the BSE. The scrip opened at Rs699.80 and has touched intraday high and low of Rs729.95 and Rs686.05 respectively.